Kuangli Bio-Tech Holdings Co (TPE:6431) EBIT: NT$-179.3 Mil (TTM As of Dec. 2025)


TPE:6431 Kuangli Bio-Tech Holdings Co Ltd TPE:6431
69 GF Score
Price NT$18.20
GF Value NT$11.76
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Kuangli Bio-Tech Holdings Co EBIT?

Kuangli Bio-Tech Holdings Co TPE:6431 -0.27% 69 EBIT is NT$-179.3 Mil as of Dec. 2025. GuruFocus rates TPE:6431 with a GF Score™ of 69/100 and a GF Value™ of NT$11.76 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Kuangli Bio-Tech Holdings Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$-50.1 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-179.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kuangli Bio-Tech Holdings Co's annualized ROC % for the quarter that ended in Dec. 2025 was -14.88%. Kuangli Bio-Tech Holdings Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -44.34%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Kuangli Bio-Tech Holdings Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -9.16%.


Kuangli Bio-Tech Holdings Co  (TPE:6431) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kuangli Bio-Tech Holdings Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-141.356 * ( 1 - 0% )/( (917.944 + 981.593)/ 2 )
=-141.356/949.7685
=-14.88 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1149.06 - 77.973 - ( 284.617 - max(0, 277.405 - 430.548+284.617))
=917.944

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1187.334 - 84.19 - ( 310.171 - max(0, 342.289 - 463.84+310.171))
=981.593

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Kuangli Bio-Tech Holdings Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-200.284/( ( (408.994 + max(39.551, 0)) + (419.1 + max(35.729, 0)) )/ 2 )
=-200.284/( ( 448.545 + 454.829 )/ 2 )
=-200.284/451.687
=-44.34 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(67.197 + 46.077 + 32.292) - (77.973 + 0 + 28.042)
=39.551

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(81.949 + 46.561 + 24.775) - (84.19 + 0 + 33.366)
=35.729

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Kuangli Bio-Tech Holdings Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-179.336/1957.628
=-9.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kuangli Bio-Tech Holdings Co EBIT Related Terms


Kuangli Bio-Tech Holdings Co EBIT Historical Data

* Premium members only.

The historical data trend for Kuangli Bio-Tech Holdings Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kuangli Bio-Tech Holdings Co EBIT Chart

Kuangli Bio-Tech Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.62 -70.21 -109.50 -166.53 -179.34

Kuangli Bio-Tech Holdings Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.10 -41.28 -49.66 -38.32 -50.07

TPE:6431 vs PG, CL, KVUE: EBIT Comparison

For the Household & Personal Products subindustry, Kuangli Bio-Tech Holdings Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kuangli Bio-Tech Holdings Co EV-to-EBIT vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Kuangli Bio-Tech Holdings Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kuangli Bio-Tech Holdings Co's EV-to-EBIT falls into.


TPE:6431
69GF Score
Kuangli Bio-Tech Holdings Co Ltd TPE:6431
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kuangli Bio-Tech Holdings Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-179.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-179.3 Mil mean?
Kuangli Bio-Tech Holdings Co (TPE:6431) has a EBIT of NT$-179.3 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Kuangli Bio-Tech Holdings Co.
Is Kuangli Bio-Tech Holdings Co's EBIT too high?
Kuangli Bio-Tech Holdings Co's current EBIT is NT$-179.3 Mil. Overall, Kuangli Bio-Tech Holdings Co has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kuangli Bio-Tech Holdings Co's EBIT compare to PG and CL?
Kuangli Bio-Tech Holdings Co's EBIT of NT$-179.3 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Consumer Packaged Goods company?
A good EBIT depends on the Consumer Packaged Goods industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Kuangli Bio-Tech Holdings Co. Kuangli Bio-Tech Holdings Co's current EBIT is NT$-179.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuangli Bio-Tech Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Kuangli Bio-Tech Holdings Co (TPE:6431) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$11.76, compared to a current price of NT$18.20 — trading 54.8% above its estimated fair value. The current EBIT is NT$-179.3 Mil. Kuangli Bio-Tech Holdings Co's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Kuangli Bio-Tech Holdings Co (TPE:6431), the current EBIT is NT$-179.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kuangli Bio-Tech Holdings Co (TPE:6431) Overvalued in 2026?

Based on GuruFocus' analysis, Kuangli Bio-Tech Holdings Co stock appears to be overvalued. The current stock price of NT$18.20 is trading 54.8% above its estimated GF Value™ of NT$11.76. GuruFocus considers Kuangli Bio-Tech Holdings Co to be Significantly Overvalued.

Key valuation signals for TPE:6431:

  • EBIT: NT$-179.3 Mil
  • GF Value™: NT$11.76 vs. price of NT$18.20 (54.8% above fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the TPE:6431 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kuangli Bio-Tech Holdings Co Business Description

Address North Sound Road, Suite 102, Cannon Place, George Town, Grand Cayman, CYM
Kuangli Bio-Tech Holdings Co Ltd is mainly engaged in the manufacture and trading of various types of panels (LENS), such as mobile phone panels, digital camera windows, PDA panels, and instrument panels. The company is also engaged in the development, manufacturing and trading of cosmetics and skin care products and other related biotechnology products. It derives revenue from Health and Wellness products, and Cosmetics and skin care products, including Lotion, Facial masks, and Other pastes. The primary source of revenue for the company is sales of cosmetic products.
69GF Score

Get the complete analysis for TPE:6431

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.20
Price
NT$11.76
GF Value